Acorn Biolabs, a Toronto, Canada-based biotechnology company, closed a $3.3m seed funding round.
Backers included Real Ventures, Globalive Technology, Pool Global Partners and Epic Capital Management and other unnamed partners.
Founded in 2017 by Steven ten Holder, Patrick Pumputis and Dr. Drew Taylor, CEO, Acorn is a biotechnology company based at JLABS in the MaRS Discovery District in Toronto, Canada, which is bringing to market a home-based, affordable and non-invasive consumer live cell collection kit and cryopreservation service. Acorn helps people collect and preserve cells to leverage them in the future when they need them.
The company intends to use the funds to add key resources to its team to ramp towards market availability.
Among them, Jacquie Chapman, an experienced industry veteran, joined Acorn as Chief Operating Officer while Sonya Verheyden joined Acorn as Chief Marketing Officer.
The company is currently planning for commercial availability of the consumer home collection and cryopreservation service in Q2 2019.